Uromigos-ASCO

The UromigosThe Uromigos | July 17, 2023
Yohann Loriot, MD, PhD, discusses the practice-changing THOR study data on the benefit of erdafitinib for advanced UC.
Listen Now
The UromigosThe Uromigos | July 25, 2023
Meredith Regan and David McDermott finalize their debate on VEGF/TKI vs IPI/NIVO for mRCC. PFS2 and TFS are also covered.
The UromigosThe Uromigos | June 21, 2023
Silke Gillessen, MD, PhD joins The Uromigos to discuss the genitourinary oncology highlights of ASCO 2023.
The UromigosThe Uromigos | June 21, 2023
The Uromigos discuss ipi/nivo combination therapy versus VEGF TKI I/O immune therapy for ccRCC with Mike Atkins, MD.
The UromigosThe Uromigos | July 10, 2023
Shilpa Gupta, MD discusses two oral abstracts from ASCO 2023 on the CONTACT-03 trial and the EV-103 trial.
The UromigosThe Uromigos | August 1, 2023
Toni Choueiri gives an overview of the CONTACT-03 trial on atezolizumab plus cabozantinib versus cabozantinib alone for mRCC.
The UromigosThe Uromigos | August 1, 2023
Karim Fizazi, MD, PhD, discusses the radiotherapy components of the PEACE-1 study on abiraterone and prednisone added to ADT.
The UromigosThe Uromigos | August 1, 2023
Karim Fizazi joins us at ASCO 2023 to discuss results from the TALAPRO-2 study on talazoparib plus enzalutamide for mCRPC.
The UromigosThe Uromigos | August 1, 2023
Drs. David McDermott and Meredith Regan discuss statistics in clinical trials and upcoming RCC presentations at ASCO 2023.
The UromigosThe Uromigos | August 1, 2023
We chat with Christopher Sweeney about the upcoming ASCO 2023 conference and what presentations to look out for.
The UromigosThe Uromigos | November 11, 2022
Veda Giri discusses germline variants among African American males and specific genes related to prostate cancer.
The UromigosThe Uromigos | November 11, 2022
Data from the ENZAMET trial reconfirms survival benefit with enzalutamide in mHSPC, but the role of docetaxel is uncertain.
The UromigosThe Uromigos | November 11, 2022
Matt Galsky discusses research posters presented that cover the effects of HER2-targeting ADCs for urothelial cancer.
The UromigosThe Uromigos | November 11, 2022
Nazli Dizman covers an update on the CBM588 probiotic strain and its phase II trial.
The UromigosThe Uromigos | November 11, 2022
Amir Goldkorn, MD, discusses findings from a phase 2 bladder trial, responses to neoadjuvant chemotherapy, and more.
The UromigosThe Uromigos | November 11, 2022
Robert Jones, MD, talks about the hypothesis for ATLANTIS, its specific trial results, and more.
The UromigosThe Uromigos | November 11, 2022
Christopher W. Ryan, MD, shares long-awaited data about adjuvant everolimus in kidney cancer, the EVEREST trial, and results.
The UromigosThe Uromigos | September 21, 2022
Silke Gillessen gives a safety update from this EORTC study focusing on fractures.
The UromigosThe Uromigos | September 21, 2022
Chris Sweeney and Silke Gillessen give their opinion of recent data on radionuclides therapy in prostate cancer.
The UromigosThe Uromigos | September 21, 2022
Dr. Kosj Yamoah of Moffitt Cancer Center describes the work he presented at ASCO 2021.
Advertisement
Advertisement